PYC Therapeutics LimitedASX: PYC

PKD - First Patient Dosed in OLE Study

· Issued by PYC Therapeutics Limited via ASX

Filed with ASX ·

pyctx.com | ACN 098 391 961 1 11 September 2026 POLYCYSTIC KIDNEY DISEASE – FIRST PATIENT DOSED IN OPEN LABEL EXTENSION STUDY • PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available • The Company is...

View Attachment

6ix hasn’t read this filing yet.

PYC Therapeutics Limited on 6ix

Story so far

Earlier from PYC Therapeutics

Later from PYC Therapeutics

All PYC Therapeutics news releases